• Diagnostic mutation profiling and validation of non small cell lung cancer small biopsy samples using a high throughput platform.

      Quinn, A; Hickson, N; Adaway, M; Priest, L; Jaeger, E; Udar, N; Keeling, C; Kamieniorz, M; Dive, Caroline; Wallace, A; et al. (2015-01-28)
      A single platform designed for the synchronous screening of multiple mutations can potentially enable molecular profiling in samples of limited tumor tissue. This approach is ideal for the assessment of advanced non small cell lung cancer (NSCLC) diagnostic specimens, which often comprise small biopsies. Therefore, we aimed in this study to validate the mass-spectrometry based Sequenom LungCarta™ panel and MassARRAY® platform using DNA extracted from a single 5 µM formalin-fixed paraffin-embedded tissue section.